Annual Report & Accounts
29.01.2008
LONDON, UK, 29 January 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is announcing that its Annual Report and Accounts for the year ended 30 September 2007, Notice of AGM and Form of Proxy for the Annual General Meeting being held on 28 February 2008 are being mailed to shareholders today. Copies of the above documents are also being submitted to the UK Listing Authority (“UKLA”) and will shortly be available for inspection at the UKLA Viewing Facility located at:
Financial Services Authority
25 The North Colonnade
Canary Wharf
LONDONE
14 5HS
The Annual Report and Accounts, Notice of AGM and Form of Proxy have been published on the Company’s web site and can be accessed and downloaded from www.optos.com/us/About-Optos/Investor-Relations/Financial-Information.
Hard copies of these documents can be requested by contacting the Company on +44 (0) 1383 843 300 or by post addressed to:
Company Secretary
OPTOS PLC
Queensferry House
Carnegie Business Campus
Dunfermline
Scotland
KY11 8GR
The Annual General Meeting is being held at the offices of Maclay Murray & Spens LLP, One London Wall, London EC2Y 5AB commencing at 11h00GMT on 28 February 2008.
- ENDS -
Enquiries
Optos plc
John McNeil, Director of Communications and +44 (0) 1383 843 337
Assistant Company Secretary +44 (0) 7870 240 325
Note to Editors
Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina, the light-sensitive area at the back of the eye. Optos' platform technology is the Panoramic200 Scanning Laser Ophthalmoscope device - known as the P200. In a quarter of a second the P200 device produces a high resolution image of up to 200 degrees or approximately 82 percent of the retina in a single capture. The image - branded the optomap® Retinal Exam - provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. The Company has regulatory clearance (CE and FDA 510(k)) to market a second device - P200MA. Optos' technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives. Optos is incorporated in Scotland under the Companies Act 1985 with registered number SC139953. The Company maintains its Registered Office at Queensferry House, Carnegie Business Campus, Dunfermline, Scotland KY11 8GR United Kingdom.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.